26
June
2019
|
13:05
Europe/London

Charity funds major new role at The University of Manchester

The Brain Tumour Charity has announced funding of £1.35m to support the appointment of the first Chair of Neuro-Oncology Translational Science at The University of Manchester.

The role has been created to help accelerate progress towards the Charity’s twin goals of doubling brain tumour survival and halving the harm caused by the disease.

The new position is designed to enhance collaboration between groups working in neuro-oncology and neuro-immunology. It will further boost Manchester’s reputation as a global centre for neuro-oncology services and research following the recent opening of the UK’s first NHS proton beam therapy machine at The Christie Hospital.

The Chair will have unique research support and resources at The University of Manchester and Manchester Cancer Research Centre, as well as from the academic neurosurgical and neuropathology team at the Manchester Centre for Clinical Neurosciences.

The Centre for Clinical Neurosciences is one of the largest of its kind in the UK, with a world class research brain tissue collection and laboratories located close to areas of patient care to facilitate sample collection and testing.

We’ve chosen Manchester because of its unique research environment, its track record in projects that translate laboratory-based work into real change for patients and strong collaboration across its affiliated hospitals
Dr David Jenkinson, Chief Scientific Officer for The Brain Tumour Charity

Dr David Jenkinson, Chief Scientific Officer for The Brain Tumour Charity, said: “We’ve chosen Manchester because of its unique research environment, its track record in projects that translate laboratory-based work into real change for patients and strong collaboration across its affiliated hospitals.

“Our decision to fund this post for the next five years reflects our determination to help develop the highest-quality workforce and build world-class leadership in research into brain tumours in the UK, with the aim of improving survival and ensuring a better quality of life for those affected by a brain tumour.

“We’re now working with the University of Manchester to appoint the new Chair, with a focus on identifying someone whose expertise, particularly in the field of neuroinflammation, will complement and enhance the work already ongoing at the University.”

Professor Robert Bristow, Director of Manchester Cancer Research Centre, said: “The Brain Tumour Charity Chair will catalyse our great ambition to build Manchester into a world leading centre for brain tumour micro environment research that reaches into the clinics at Salford Royal NHS Foundation Trust and the Christie NHS Trust and that will hopefully lead to new local and systemic treatments for an otherwise fatal disease.”

Professor Stuart Allan, Research Domain Director for Neuroscience and Mental Health at the University of Manchester adds “This is an exciting development that really catalyses our ambitions for neuro-oncology research across Manchester.”

Share this page